Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.

Frontiers in aging neuroscience·2026
Same author

Exploring Free Will Beliefs and Attitudes Towards Punishment in Norway, Sweden and the United Kingdom.

Behavioral sciences (Basel, Switzerland)·2026
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Characterization of a novel homozygous CTSD variant causing adult-onset neuronal ceroid lipofuscinosis type 10: a case report.

Journal of neurology·2026
Same author

The Epidemiology and Clinical Presentation of the Acute Imbalance Syndrome (AIS)-A Systematic Review and Meta-Analysis.

European journal of neurology·2026
Same author

Perinatal mAChR-mediated activation of cortical subplate neurons elicits network activity driving basket cell differentiation.

Frontiers in cellular neuroscience·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Carla Palleis1,2,3, Nicolai Franzmeier4,5,6,7, Johannes Gnörich2

  • 1German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

18F-PI-2620 tau-PET imaging aids in diagnosing Progressive Supranuclear Palsy (PSP) by identifying 4-repeat tau (4RT) pathology. This biomarker shows potential for earlier, more accurate PSP diagnosis and patient stratification for clinical trials.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Radiology
  • Neuropathology

Background:

  • Progressive Supranuclear Palsy (PSP) is a challenging 4-repeat tauopathy with heterogeneous clinical presentations.
  • Current clinical criteria for PSP diagnosis lack sensitivity and specificity, especially in early stages.
  • 18F-PI-2620 tau-PET is an emerging in vivo imaging biomarker for detecting 4-repeat tau (4RT) deposits.

Purpose of the Study:

  • To evaluate the clinical utility of 18F-PI-2620 tau-PET in diagnosing PSP.
  • To determine if 4RT positivity assessed by 18F-PI-2620 tau-PET predicts increased diagnostic certainty for PSP.

Main Methods:

  • A prospective, monocentric cohort study at LMU Hospital Munich (Oct 2018 - Dec 2024).
  • Included 342 patients with a pre-PET differential diagnosis of PSP.
  • 18F-PI-2620 tau-PET imaging with expert visual assessment of 4RT pathology and clinical follow-up (12-24 months).

Main Results:

  • Of 200 patients with follow-up, 137 (68.5%) were 4RT-positive by tau-PET.
  • 18F-PI-2620 tau-PET correctly identified patients progressing along 4RT clinical spectra.
  • 79% of tau-PET-positive patients showed increased diagnostic certainty for PSP, with 95.5% of non-PSP diagnoses linked to negative tau-PET.

Conclusions:

  • 18F-PI-2620 tau-PET effectively identifies patients with 4RT pathology consistent with PSP progression.
  • This tau-PET tracer supports biomarker-based diagnosis, improving sensitivity and specificity over clinical criteria alone.
  • 18F-PI-2620 tau-PET can transform PSP diagnosis, enabling earlier detection and patient stratification for trials.